Aigen Investment Management LP Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Aigen Investment Management LP purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,538 shares of the company's stock, valued at approximately $371,000.

A number of other hedge funds also recently bought and sold shares of the company. Amalgamated Bank lifted its stake in shares of Vaxcyte by 8.6% in the third quarter. Amalgamated Bank now owns 4,081 shares of the company's stock worth $466,000 after buying an additional 322 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Vaxcyte by 186.2% in the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after acquiring an additional 34,287 shares during the last quarter. Atria Investments Inc bought a new position in Vaxcyte in the 3rd quarter valued at approximately $286,000. TimesSquare Capital Management LLC purchased a new stake in Vaxcyte during the 3rd quarter valued at $30,752,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Vaxcyte in the 3rd quarter worth $1,016,000. Institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has an average rating of "Buy" and an average price target of $147.50.

Remove Ads

Insider Activity

In related news, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,208,443.70. The trade was a 3.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,250 shares of company stock valued at $4,550,258 in the last ninety days. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Trading Up 1.4 %

NASDAQ PCVX traded up $0.96 during trading hours on Tuesday, hitting $69.85. 973,108 shares of the company's stock traded hands, compared to its average volume of 1,189,999. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The firm has a market capitalization of $8.99 billion, a P/E ratio of -15.18 and a beta of 1.02. The business's fifty day moving average price is $83.06 and its two-hundred day moving average price is $94.66.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.